Osimertinib With or Without Chemotherapy in Advanced Non-Small Cell Lung Cancer With EGFR and Concurrent TP53...

Area of Science:

• Oncology
• Pharmacology
• Clinical Trials

Background:

• Combination therapy is a promising approach for EGFR-mutated non-small cell lung cancer (NSCLC).
• Identifying optimal combination regimens and patient subgroups remains crucial for improving treatment outcomes.
• The benefit-risk profile of combination therapies requires careful evaluation.

Purpose of the Study:

• To compare the efficacy and safety of first-line osimertinib plus chemotherapy versus osimertinib monotherapy.
• To evaluate outcomes in patients with EGFR-mutated advanced NSCLC and concurrent TP53 mutations.
• To determine the progression-free survival and overall survival benefits of combination therapy.

Main Methods:

• A multicenter, randomized, open-label, phase 3 study enrolled 294 treatment-naive patients with EGFR-mutated NSCLC and TP53 mutations.
• Patients received either osimertinib plus chemotherapy (pemetrexed and carboplatin) or osimertinib monotherapy.
• The primary endpoint was investigator-assessed progression-free survival; secondary endpoints included overall survival and safety.

Main Results:

• Median progression-free survival was significantly longer with osimertinib plus chemotherapy (34.0 months) compared to monotherapy (15.6 months).
• The combination therapy demonstrated a hazard ratio of 0.44 (P < .001) for progression-free survival.
• Grade 3 or higher adverse events were more frequent with combination therapy, but no new safety signals emerged.

Conclusions:

• Osimertinib plus chemotherapy significantly increases progression-free survival in patients with EGFR-mutated NSCLC and concurrent TP53 mutations.
• This combination therapy provides a clinical rationale for individualized treatment strategies in advanced NSCLC.
• Further data on overall survival will provide a more complete picture of the long-term benefits.